Illert, A. L.
Stenzinger, A. http://orcid.org/0000-0003-1001-103X
Bitzer, M. http://orcid.org/0000-0002-4463-8263
Horak, P. http://orcid.org/0000-0003-4536-9306
Gaidzik, V. I.
Möller, Y.
Beha, J.
Öner, Ö.
Schmitt, F.
Laßmann, S.
Ossowski, S.
Schaaf, C. P.
Hallek, M.
Brümmendorf, T. H. http://orcid.org/0000-0002-9677-3723
Albers, P.
Fehm, T.
Brossart, P.
Glimm, H.
Schadendorf, D. http://orcid.org/0000-0003-3524-7858
Bleckmann, A.
Brandts, C. H. http://orcid.org/0000-0003-1732-2535
Esposito, I.
Mack, E.
Peters, C.
Bokemeyer, C.
Fröhling, S. http://orcid.org/0000-0001-7907-4595
Kindler, T.
Algül, H. http://orcid.org/0000-0002-5067-7031
Heinemann, V.
Döhner, H. http://orcid.org/0000-0003-2116-5536
Bargou, R. http://orcid.org/0000-0002-1221-7421
Ellenrieder, V.
Hillemanns, P.
Lordick, F.
Hochhaus, A.
Beckmann, M. W.
Pukrop, T.
Trepel, M.
Sundmacher, L.
Wesselmann, S.
Nettekoven, G.
Kohlhuber, F.
Heinze, O.
Budczies, J. http://orcid.org/0000-0002-6668-5327
Werner, M.
Nikolaou, K.
Beer, A. J.
Tabatabai, G.
Weichert, W.
Keilholz, U.
Boerries, M.
Kohlbacher, O. http://orcid.org/0000-0003-1739-4598
Duyster, J.
Thimme, R. http://orcid.org/0000-0003-1417-4135
Seufferlein, T.
Schirmacher, P.
Malek, N. P.
Funding for this research was provided by:
Innovationsfond of the Joint federal committee, Germany
Deutsche Krebshilfe (Mildre-Scheel-Professorship)
Article History
First Online: 6 June 2023
Competing interests
: A.L.I. received honoraria for consulting and advisory boards from Janssen-Cilag, AbbVie, Roche, AstraZeneca, Amgen and Takeda. A.S. has received honoraria for consulting and/or advisory boards from Agilent, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, and Thermo Fisher; and grants from Bayer, BMS, Chugai, and Incyte. M.B. received honoraria for advisory boards from Roche, Incyte Biosciences Germany, Bayer Vital, BMS, MSD Sharp & Dome, Taiho Oncology Europe, and EISAI. V.I.G. is on the advisory board for Jazz Pharmaceuticals and Abbvie; received speakers bureau fees for Pfizer, Janssen, and Abbvie; and travel support from Abbvie. S.L. reports research grant from BMS, advisory board/speaker invitation from AstraZeneca, Eli Lily, Roche, and Takeda outside of this work. S.O. received honoraria for workshop presentations at conferences from Illumina. M.H. received honoraria for lectures, presentations, speakers bureaus and consulting advisory boards from Abbvie, Roche, AstraZeneca, Gilead, Janssen, and Beigene. P.A. received fees from Ferring Pharmaceuticals and Bayer. T.F. received honoraria from Onkowissen. P.B. received honoraria for consulting and advisory boards from Bristol Myers Squibb, AstraZeneca, Amgen, and MSD. D.S. has been on the advisory board, an invited speaker, or committee member for BMS, Immunocore, Merck Serono, MSD, Neracare, Novartis, Pfizer, Philogen, Pierre Fabre, Roche, Sanofi, and Regeneron; received research grants from or been principal investigator for BMS, MSD, Novartis, Philogen, Pierre Fabre, and Sanofi; and is a member of the board of directors for EORTC-MG. A.B. received honoraria for consulting and advisory boards from MSD, Boehringer Ingelheim, Takeda, AstraZeneca, BMS, Lilly, Roche Pharma, Pfizer, Sanofi, Janssen-Cilag, Bayer Vital, Amgen, Novartis, and Daiichi Sankyo. C.H.B. received honoraria for consulting and advisory boards from MSD, BMS and Novartis. I.E. received consulting fees from Incyte Bioscience International. E.M. received speaker honoraria from Roche and Boehringer Ingelheim; and is on an advisory board for Roche. C.B. has been on the advisory board, an invited speaker, or committee member for AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Bristol Myers Squipp, Jansen Cilag, Med Update, Merck Serono, Oncology Drug Consult CRO, Roche Pharma, and Sanofi Aventis; several clinical trials sponsored by industry; member of board of directors for DGHO and Northern German Society of Internal Medicine; leadership roles at Hamburg Cancer Society and National Network of German Cancer Centers (DKH); and advisory role at board of DGHO advisors. S.F. received consulting fees or advisory board membership from Bayer, Illumina, and Roche; honoraria from Amgen, Eli Lilly, PharmaMar, and Roche; research funding from AstraZeneca, Pfizer, PharmaMar, and Roche; and travel or accommodation expenses from Amgen, Eli Lilly, Illumina, PharmaMar, and Roche. H.A. received honoraria for consulting and advisory boards from AstraZeneca, Viatris, Pfizer, and Servier. V.H. declares honoraria for talks and advisory board roles from Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Celgene, Terumo, Oncosil, Seagen, and NORDIC Pharma; and research funding from Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, SIRTEX, and Servier. R.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex, and Gemoab. P.H. received honoraria from MSD and AstraZeneca. F.L. received honoraria from Astellas, AstraZeneca, BMS, MSD, and Roche. A.H. received research support from Novartis, BMS, Pfizer, and Incyte. M.T. received honoraria for consulting or advisory boards from Janssen-Cilag, Roche, AstraZeneca, Amgen, Takeda, BMS, IO Medico, Sana, RKH Kliniken, ConEvent, Med Update, VHS Stadtbergen, I-Med Institut, and Klinikum Esslingen. J.B. received honoraria from MSD. M.W. reports research grant from BMS outside of this work. A.J.B. received honoraria for talks, consulting, or advisory boards from Siemens Healthineers, NVision, and AAA/Novartis. G.T. has served on advisory boards for Bayer, Boehringer Ingelheim, CureVac, and Novocure, consulted for Bayer, Boehringer Ingelheim, and CureVac; was a steering committee member in non-interventional trials for Bayer and Novocure; with financial compensation for all these activities provided as institutional funding to the University Hospital Tübingen. W.W. received research grants from Roche, MSD, BMS, and AstraZeneca; advisory board, lectures, speaker bureaus fees from Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Janssen, Amgen, Astellas, Illumina, Eisai, Siemens, Agilent, ADC, GSK, and Molecular Health. U.K. received research support from AstraZeneca; and honoraria from BMS, MSD, Merck, and Novartis. T.S. received honoraria for consulting of editorial boards for Servier, M&D, BMS, Mirati, Olympus Fondation Pierre Fabre, and Eli Lilly. P.S. received honoraria from speakers bureau or advisory boards for Incyte, BMS, Eisai, MSD, AstraZeneca, and Amgen; and from BMS, Gilead, Incyte, and Huygai. All other authors declare no competing interests.